Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing
Posted:
Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped Sangamo said it is now looking for a new partner for the program.
Read the full article in the latest MedCity News blog post here.
As we step into 2025, we’re excited to continue innovating, collaborating, and transforming healthcare together.
This year, let’s work towards improving health and well-being across the UK and beyond.
Mark your calendars!
Join us on 8th & 9th December 2025…
Cancer in children and adolescents is rare. Nevertheless, malignant diseases are still one of the most common causes of death in this age group. Survivors of childhood or adolescent cancer often suffer chronic health problems with increased morbidity and mortality…
Attendees
Sponsors and
Exhibitors
Webinars
Contact us